Literature DB >> 11834714

Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure.

Antony Y Kim1, Peter L Walinsky, Frank D Kolodgie, Ce Bian, Jason L Sperry, Clayton B Deming, Eric A Peck, Jay G Shake, Gregory B Ang, Richard H Sohn, Charles T Esmon, Renu Virmani, R Scott Stuart, Jeffrey J Rade.   

Abstract

Thrombosis is the major cause of early vein graft failure. Our aim was to determine whether alterations in the expression of the anticoagulant proteins, thrombomodulin (TM) and the endothelial cell protein C receptor (EPCR), impair endothelial thromboresistance that may contribute to vein graft failure. Immunohistochemical staining of autologous rabbit vein graft sections revealed that the expression of TM, but not EPCR, was reduced significantly early after graft implantation. Western blot analysis revealed that TM expression was reduced by >95% during the first 2 weeks after implantation, with gradual but incomplete recovery by 42 days. This resulted in up to a 95% reduction in the capacity of the grafts to activate protein C and was associated with an increase in bound thrombin activity, which peaked on day 7 at 28.7 +/- 3.8 mU/cm(2) and remained elevated for more than 14 days. Restoration of TM expression using adenovirus vector-mediated gene transfer significantly enhanced the capacity of grafts to activate protein C and reduced bound thrombin activity on day 7 to levels comparable to that of normal veins (5.7 +/- 0.4 versus 5.2 +/- 1.1 mU/cm(2), respectively, P=0.74). Surprisingly, neointima formation was not affected by this inhibition of local thrombin activity. These data suggest that the early loss of TM expression significantly impairs vein graft thromboresistance and results in enhanced local thrombin generation. Although enhanced local thrombin generation may predispose to early vein graft failure due to thrombosis, it does not seem to contribute significantly to late vein graft failure due to neointimal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834714     DOI: 10.1161/hh0202.105097

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  18 in total

Review 1.  Gene therapy for the prevention of vein graft disease.

Authors:  Kevin W Southerland; Sarah B Frazier; Dawn E Bowles; Carmelo A Milano; Christopher D Kontos
Journal:  Transl Res       Date:  2012-12-27       Impact factor: 7.012

2.  Patient-derived endothelial progenitor cells improve vascular graft patency in a rodent model.

Authors:  J D Stroncek; L C Ren; B Klitzman; W M Reichert
Journal:  Acta Biomater       Date:  2011-09-06       Impact factor: 8.947

3.  Simulated surface-induced thrombin generation in a flow field.

Authors:  S W Jordan; E L Chaikof
Journal:  Biophys J       Date:  2011-07-20       Impact factor: 4.033

4.  Inhibition of transforming growth factor-β restores endothelial thromboresistance in vein grafts.

Authors:  Navin K Kapur; Ce Bian; Edward Lin; Clayton B Deming; Jason L Sperry; Baranda S Hansen; Nikolaos Kakouros; Jeffrey J Rade
Journal:  J Vasc Surg       Date:  2011-07-31       Impact factor: 4.268

5.  Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors.

Authors:  Toyoko Hiroi; Clayton B Deming; Haige Zhao; Baranda S Hansen; Elisabeth K Arkenbout; Thomas J Myers; Michael A McDevitt; Jeffrey J Rade
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

Review 6.  Advanced drug delivery systems for antithrombotic agents.

Authors:  Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

7.  In vitro functional testing of endothelial progenitor cells that overexpress thrombomodulin.

Authors:  John D Stroncek; Yujing Xue; Nabila Haque; Jeffrey H Lawson; William M Reichert
Journal:  Tissue Eng Part A       Date:  2011-05-25       Impact factor: 3.845

8.  Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin.

Authors:  Daria K Moaveni; Erin M Lynch; Cathy Luke; Vikram Sood; Gilbert R Upchurch; Thomas W Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2008-03       Impact factor: 4.268

9.  Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation.

Authors:  Bi-Sen Ding; Nankang Hong; Melpo Christofidou-Solomidou; Claudia Gottstein; Steven M Albelda; Douglas B Cines; Aron B Fisher; Vladimir R Muzykantov
Journal:  Am J Respir Crit Care Med       Date:  2009-04-02       Impact factor: 21.405

10.  Activated protein C improves the severity of severe acute pancreatitis via up-regulating the expressions of endothelial cell protein C receptor and thrombomodulin.

Authors:  Chen Ping; Zhang Yongping; Qiao Minmin; Yao Weiyan; Yuan Yaozong
Journal:  Dig Dis Sci       Date:  2009-08-13       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.